title: Liver-X-receptor activator prevents homocysteine-induced production of IgG antibodies from murine B lymphocytes via the ROS-NF-kappaB pathway.
abstract: Our previous study showed that homosysteine (Hcy) promotes proliferation of mouse splenic B lymphocytes. In this study, we investigated whether Hcy could stimulate the production of IgG antibodies. Hcy significantly increased the production of IgG antibodies from resting B lymphocytes. B lymphocytes from ApoE-knockout mice with hyperhomocysteinemia showed elevated IgG secretion at either the basal Hcy level or in response to lipopolysaccharide. Hcy promoted reactive oxygen species (ROS) formation, and free radical scavengers, MnTMPyP decreased Hcy-induced IgG secretion. The inhibitor of NF-kappaB (MG132) also significantly reduced Hcy-induced IgG secretion. Furthermore, Hcy-induced formation of ROS, activation of NF-kappaB, and secretion of IgG could be inhibited by the liver-X-receptor (LXR) agonist T0901317. Thus, our data provide strong evidence that HHcy induces IgG production from murine splenic B lymphocytes both in vitro and in vivo. The mechanism might be through the ROS-NF-kappaB pathway and can be attenuated by the activation of LXR.
authors: Institute of Vascular Medicine, Peking University Third Hospital, Peking University, Beijing 100083, PR China.
authors: Lina
authors: L
authors: Chang
authors: Zhenmin
authors: Z
authors: Zhang
authors: Wenjing
authors: W
authors: Li
authors: Jing
authors: J
authors: Dai
authors: Youfei
authors: Y
authors: Guan
authors: Xian
authors: X
authors: Wang
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000235:genetics / Q000502:physiology; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D002460:Cell Line; D004268:DNA-Binding Proteins / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D006710:Homocysteine / Q000494:pharmacology*; D006801:Humans; D006845:Hydrocarbons, Fluorinated; D020138:Hyperhomocysteinemia / Q000503:physiopathology; D007074:Immunoglobulin G / Q000096:biosynthesis*; D007976:Leupeptins / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D000071518:Liver X Receptors; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D008665:Metalloporphyrins / Q000494:pharmacology; D051379:Mice; D018345:Mice, Knockout; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D057093:Orphan Nuclear Receptors; D017382:Reactive Oxygen Species / Q000037:antagonists & inhibitors / Q000378:metabolism*; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D013449:Sulfonamides / Q000494:pharmacology; D013997:Time Factors; D014162:Transfection; D005466:Fluorocarbons; D000096926:Benzenesulfonamides
chemical_list: D001057:Apolipoproteins E; D004268:DNA-Binding Proteins; D006710:Homocysteine; D006845:Hydrocarbons, Fluorinated; D007074:Immunoglobulin G; D007976:Leupeptins; D008070:Lipopolysaccharides; D000071518:Liver X Receptors; D008156:Luciferases; D008665:Metalloporphyrins; D016328:NF-kappa B; D057093:Orphan Nuclear Receptors; D017382:Reactive Oxygen Species; D018160:Receptors, Cytoplasmic and Nuclear; D011993:Recombinant Fusion Proteins; D013449:Sulfonamides; C502230:Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin; C423915:T0901317; D005466:Fluorocarbons; D000096926:Benzenesulfonamides; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde